CareDx/$CDNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CareDx
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Ticker
$CDNA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
647
ISIN
US14167L1035
Website
CareDx Metrics
BasicAdvanced
$1.1B
17.71
$1.07
2.28
-
Price and volume
Market cap
$1.1B
Beta
2.28
52-week high
$34.84
52-week low
$13.48
Average daily volume
1.2M
Financial strength
Current ratio
4.107
Quick ratio
3.546
Long term debt to equity
6.346
Total debt to equity
7.981
Profitability
EBITDA (TTM)
-25.227
Gross margin (TTM)
67.64%
Net profit margin (TTM)
17.92%
Operating margin (TTM)
-11.32%
Effective tax rate (TTM)
0.72%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-5.20%
Return on equity (TTM)
19.54%
Valuation
Price to earnings (TTM)
17.71
Price to revenue (TTM)
2.948
Price to book
2.78
Price to tangible book (TTM)
3.5
Price to free cash flow (TTM)
50.685
Free cash flow yield (TTM)
1.97%
Free cash flow per share (TTM)
37.55%
Growth
Revenue change (TTM)
25.92%
Earnings per share change (TTM)
-130.71%
3-year revenue growth (CAGR)
3.95%
10-year revenue growth (CAGR)
28.33%
3-year earnings per share growth (CAGR)
4.29%
10-year earnings per share growth (CAGR)
47.56%
What the Analysts think about CareDx
Analyst ratings (Buy, Hold, Sell) for CareDx stock.
Bulls say / Bears say
CareDx reported a 31% year-over-year increase in revenue for Q2 2024, reaching $92.3 million, indicating strong financial growth. (Investing.com)
The company achieved a positive adjusted EBITDA of $12.9 million in Q2 2024, a significant turnaround from a loss in the same quarter of the previous year. (Investing.com)
Analysts have set a 12-month average price target of $32.20 for CareDx, suggesting potential upside from current levels. (Benzinga)
A federal judge overturned a $96 million jury verdict against CareDx in February 2025, potentially impacting the company's financial outlook. (Reuters)
Wells Fargo downgraded CareDx from 'Underweight' to 'Equal Weight' in January 2025, reducing the price target from $28 to $24, indicating cautious sentiment. (MarketScreener)
Insider selling activity, including significant share sales by company directors in August 2024, may raise concerns about internal confidence. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
CareDx Financial Performance
Revenues and expenses
CareDx Earnings Performance
Company profitability
CareDx News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CareDx stock?
CareDx (CDNA) has a market cap of $1.1B as of June 20, 2025.
What is the P/E ratio for CareDx stock?
The price to earnings (P/E) ratio for CareDx (CDNA) stock is 17.71 as of June 20, 2025.
Does CareDx stock pay dividends?
No, CareDx (CDNA) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next CareDx dividend payment date?
CareDx (CDNA) stock does not pay dividends to its shareholders.
What is the beta indicator for CareDx?
CareDx (CDNA) has a beta rating of 2.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.